ID2 Promotes Tumor Progression and Metastasis in Thyroid Cancer

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Jan 10

PMID 38195969

Authors

Zhongming Deng

Min Xu

ZhengHua Ding

Jianqiao Kong

Juanjuan Liu

Zelin Zhang

Ping Cao

Affiliations

Soon will be listed here.

Abstract

Background: Inhibitor of DNA Binding 2 (ID2) plays a crucial role in tumor cell proliferation, invasion, metastasis, and stemness. Aberrant ID2 expression is associated with poor prognosis in various cancers. However, the specific function of ID2 in thyroid cancer remain unclear.

Method: The TCGA database were utilized to explore the clinical relevance of ID2 in cancer. GO, KEGG, and TIMER were employed to predict the potential roles of ID2 in cancer. Functional analysis, including CCK-8, colony formation, transwell, wound healing, and sphere formation experiments, were conducted to determine the biological functions of ID2 in human cancers. Western blot (WB), RT-qPCR, and immunohistochemical (IHC) analyses were used to investigate the relationship between ID2 and downstream targets.

Results: Our study revealed significant overexpression of ID2 in various malignant tumor cells. Knocking ID2 significantly inhibited cancer cell proliferation and invasion, while overexpressing ID2 enhanced these capabilities. Additionally, ID2 mediates resistance of cancer cells to protein kinase B (or Akt) inhibitions. Further WB and IHC experiments indicated that ID2 promotes the phosphorylation activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, thereby upregulating the expression of downstream proliferation, epithelial-mesenchymal transition (EMT), and stemness-related markers.

Conclusion: We found that ID2 significantly promotes thyroid cancer cell proliferation, migration, EMT, and stemness through the PI3K/Akt pathway. Moreover, ID2 plays a crucial role in regulating cancer immune responses. It may serve as a potential biomarker for enhancing the efficacy of chemotherapy, targeted therapy, and immunotherapy against cancer.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Coppe J, Itahana Y, Moore D, Bennington J, Desprez P . Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res. 2004; 10(6):2044-51. DOI: 10.1158/1078-0432.ccr-03-0933. View

Carey J, Asirvatham A, Galm O, Ghogomu T, Chaudhary J . Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer. BMC Cancer. 2009; 9:173. PMC: 2700118. DOI: 10.1186/1471-2407-9-173. View

Zielinski A, Fong S, Allison J, Kawahara M, Coppe J, Feiler H . The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. Int J Cancer. 2009; 126(10):2490-6. DOI: 10.1002/ijc.24811. View

Sharma P, Patel D, Chaudhary J . Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med. 2013; 1(2):187-97. PMC: 3544440. DOI: 10.1002/cam4.19. View

OBrien C, Kreso A, Ryan P, Hermans K, Gibson L, Wang Y . ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell. 2012; 21(6):777-92. DOI: 10.1016/j.ccr.2012.04.036. View

Majidpoor J, Mortezaee K . Steps in metastasis: an updated review. Med Oncol. 2021; 38(1):3. DOI: 10.1007/s12032-020-01447-w. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Pal M, Bhattacharya S, Kalyan G, Hazra S . Cadherin profiling for therapeutic interventions in Epithelial Mesenchymal Transition (EMT) and tumorigenesis. Exp Cell Res. 2018; 368(2):137-146. DOI: 10.1016/j.yexcr.2018.04.014. View

10.

Paul M, Schneeweis C, Falcomata C, Shan C, Rossmeisl D, Koutsouli S . Non-canonical functions of SNAIL drive context-specific cancer progression. Nat Commun. 2023; 14(1):1201. PMC: 9992512. DOI: 10.1038/s41467-023-36505-0. View

11.

Liu X, Sun H, Qi J, Wang L, He S, Liu J . Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol. 2013; 15(7):829-38. DOI: 10.1038/ncb2765. View

12.

Zeng S, Zhang Y, Ma J, Deng G, Qu Y, Guo C . BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2. Cancer Lett. 2017; 390:67-76. DOI: 10.1016/j.canlet.2016.12.042. View

13.

Liu F, Chen S, Yu Y, Huang C, Chen H, Wang L . Inhibitor of DNA binding 2 knockdown inhibits the growth and liver metastasis of colorectal cancer. Gene. 2022; 819:146240. DOI: 10.1016/j.gene.2022.146240. View

14.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

15.

Janku F, Yap T, Meric-Bernstam F . Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018; 15(5):273-291. DOI: 10.1038/nrclinonc.2018.28. View

16.

Zhang Y, Ng P, Kucherlapati M, Chen F, Liu Y, Tsang Y . A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017; 31(6):820-832.e3. PMC: 5502825. DOI: 10.1016/j.ccell.2017.04.013. View

17.

Pappa T, Ahmadi S, Marqusee E, Johnson H, Nehs M, Cho N . Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021; 27(15):4256-4264. DOI: 10.1158/1078-0432.CCR-21-0874. View

18.

Garcia-Rostan G, Costa A, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem M . Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005; 65(22):10199-207. DOI: 10.1158/0008-5472.CAN-04-4259. View

19.

Ricarte-Filho J, Ryder M, Chitale D, Rivera M, Heguy A, Ladanyi M . Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69(11):4885-93. PMC: 2690720. DOI: 10.1158/0008-5472.CAN-09-0727. View

20.

Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K . Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008; 93(8):3106-16. DOI: 10.1210/jc.2008-0273. View